Publication
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics
Journal Paper/Review - Apr 21, 2020
Luftner Diana, Fehm Tanja N, Tesch Hans, Overkamp Friedrich, Welslau Manfred, Pöschke Patrik, Kolberg Hans-Christian, Fasching Peter A, Huober Jens, Thill Marc, Schütz Florian, Belleville Erik, Ettl Johannes, Janni Wolfgang, Wöckel Achim, Müller Volkmar, Hartkopf Andreas D, Schneeweiss Andreas, Lux Michael P
Units
PubMed
Doi
Citation
Type
Journal
Publication Date
Issn Print
Pages
Brief description/objective
For patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD-L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with their data. In addition, two innovative anti-HER2 therapies are presented (trastuzumab-deruxtecan and tucatinib) for which the results from new studies have been reported. Molecular tests offer the possibility of defining patient populations or also monitoring courses of therapy. This can help identify patients with specific characteristics in order to provide them with individually targeted therapy within the framework of studies. In a large study, the benefit of such a biomarker study was able to be described for the first time.